FOCUSING ON THE FUTURE OF BIOLOGICS MANUFACTURING
Business Drivers
More Biologic Drugs & Emergence of Biosimilars
- Impacting Technologies
- Greater Demands on Development
- Higher Titers
- Greater Efficiency
- Higher Utilization
Dyadic believes that the C1 technology’s high productivity provides the potential to dramatically lower biologic vaccine and drug CapEx and OpEx
When a 10,000 liter production fermenter can be reduced to a 1,000 liter production fermenter the savings are significant in at least 3 ways:
- Capital investment required to build launch capacity
- Factory with launch capacity needs to be constructed 24 month before FDA approval, or very costly CMO
- FDA license easier for small factory